Trekresil® (Tablets) Instructions for Use
Marketing Authorization Holder
Rionipharm LLC (Russia)
Manufactured By
Aromasintez, LLC (Russia)
ATC Code
A13A (General tonic preparations)
Active Substance
Oxyethylammonium methylphenoxy acetate (Grouping name)
Dosage Form
| Trekresil® | Tablets 200 mg: 10, 20, 30 or 50 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or white with a yellowish tint, round, flat-cylindrical, with a bevel and a score line.
| 1 tab. | |
| Oxyethylammonium methylphenoxy acetate | 200 mg |
Excipients: lactose monohydrate – 200 mg, potato starch – 95 mg, calcium stearate – 5 mg.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
Clinical-Pharmacological Group
Preparation with adaptogenic and restorative action
Pharmacotherapeutic Group
Adaptogenic agent
Pharmacological Action
Adaptogenic agent. Stimulates the production of alpha and gamma interferons, affects the immune status of the body by activating the cellular and humoral links of immunity, stimulates the phagocytic activity of macrophages.
It strengthens the body’s immune system, increases endurance during physical and mental stress, reduces the effect of various toxins, increases the body’s resistance to hypoxia, low and high temperatures and other adverse environmental factors.
Pharmacokinetics
Oxyethylammonium methylphenoxy acetate has high bioavailability, is rapidly metabolized in the liver, and is excreted by the kidneys mainly in the form of glucuronides. It does not accumulate in the body with long-term use.
Indications
As part of complex therapy: for the prevention and treatment of acute respiratory viral infections; during periods of high intellectual and heavy physical exertion; to increase the body’s resistance to various stressful influences (hypoxia, overheating, hypothermia) and adverse environmental influences (sudden climate change, adaptation to changes in atmospheric pressure).
ICD codes
| ICD-10 code | Indication |
| J06.9 | Acute upper respiratory infection, unspecified |
| T67 | Effects of heat and light |
| T68 | Hypothermia |
| T70 | Effects of air pressure and water pressure |
| Z57 | Occupational exposure to risk factors |
| Z73.3 | Stress, not elsewhere classified (physical and mental strain) |
| ICD-11 code | Indication |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| NF01.Z | Exposure to heat, unspecified |
| NF02 | Hypothermia |
| NF04.Z | Exposure to atmospheric pressure and water pressure, unspecified |
| QD84.Z | Exposure to occupational risk factors, unspecified |
| QE01 | Stress, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer Trekresil®orally with water.
For acute respiratory viral infections (ARVI) prevention and treatment, take 200 mg (1 tablet)twice daily for a 10-day course.
To manage high intellectual or physical stress, take 200 mg (1 tablet)once or twice daily. Limit the course duration to two weeks.
For enhancing resistance to stressful environmental factors (e.g., climate change, hypoxia), initiate a 200 mg (1 tablet)once or twice daily regimen 1-2 days prior to expected exposure. Continue throughout the exposure period.
Do not exceed a single dose of 200 mg or a daily dose of 400 mg.
For patients with hepatic or renal impairment, no dose adjustment is required.
Discontinue use if severe disease symptoms persist or worsen and consult a physician.
Adverse Reactions
Rarely allergic reactions – hypersensitivity reactions, anaphylactic shock, anaphylaxis, angioedema.
Contraindications
Hypersensitivity to the active substance; children under 12 years of age; pregnancy, breastfeeding period.
Use in Pregnancy and Lactation
Use is contraindicated during pregnancy and breastfeeding.
Use in Hepatic Impairment
The drug is approved for use in patients with impaired liver function.
Use in Renal Impairment
The drug is approved for use in patients with impaired renal function.
Pediatric Use
Use in children under 12 years of age is contraindicated (due to the lack of data on efficacy and safety of use).
Geriatric Use
Use in elderly patients is permitted.
Special Precautions
If, during the use of the product, pronounced symptoms of the disease persist or worsen in patients with ARVI, the product should be discontinued and a doctor should be consulted.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Kagocel pills 12mg, 30pcs
Phenibut-Vertex pills 250mg, 20pcs
Belosalic, lotion solution for external use spray 100ml
Noopept, pills 10mg, 50pcs
OKI, sachets 80mg 2g, 12pcs
Mildronate capsules 500mg, 90pcs
Fenotropil pills 100mg, 60pcs
Belosalic, ointment, 30g
Daivobet, ointment, 30g
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Actovegin pills 200mg, 50pcs
Nootropil pills 800mg, 30pcs
No-spa pills 40mg, 64pcs
Arbidol, capsules 100mg, 40pcs
Ingavirin capsules 90mg, 10pcs
Picamilon pills 50mg, 60pcs 